투자판단관련주요경영사항 (HCP18034 개발을 위한 식약처(MFDS) 제3상 임상시험 계획 승인)[유]
Received: 5/29/2026 · Reporter: 한미약품
한미약품은 HCP18034 개발을 위한 식약처로부터 제3상 임상시험 계획 승인을 받았습니다.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 82 filings
- Same category
- 33 filings
- Previous same-category filing
- 4/30/2026(29 days ago)
- Corrections / withdrawals
- 0 filings
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).